Literature DB >> 21468575

Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro.

Wenzhong Que1, Junmin Chen.   

Abstract

c-Met, a receptor tyrosine kinase and its ligand, hepatocyte growth factor, are critical in cellular proliferation, motility and invasion and confer resistance to specific chemotherapeutic drugs. However, little is known about the impact of c-Met knockdown on the biological functions of human multiple myeloma U266 cells. The present study was designed to determine the role of c-Met in the proliferation and invasion of U266 cells, using RNA interference technology in vitro. In our study, the c-Met short hairpin RNA (shRNA) was successfully transfected into U266 cells, which resulted in the significant inhibition of transcription and expression of c-Met. The down-regulation of c-Met inhibited the proliferation potential, adherence and invasiveness of U266 cells, and also increased chemosensitivity to doxorubicin. The c-Met shRNA in U266 cells induced apoptosis and increased the accumulation of cleavage PARP and cleavage caspase-3. However, the expression of Bcl-2 and Bax did not change following the c-Met knockdown. Taken together, our data reveal that the down-regulation of c-Met inhibits proliferation and invasion and increases the chemosensitivity of U266 cells. Thus, the targeting of c-Met could be an effective therapeutic approach against multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21468575     DOI: 10.3892/mmr.2011.426

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  11 in total

1.  Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines.

Authors:  T-H Hung; Y-H Li; C-P Tseng; Y-W Lan; S-C Hsu; Y-H Chen; T-T Huang; H-C Lai; C-M Chen; K-B Choo; K-Y Chong
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

2.  Antiproliferation activities of NK4 on multiple myeloma.

Authors:  Wenzhong Que; Huili Liu; Qinqin Yang; Shanghua Xu
Journal:  Exp Ther Med       Date:  2018-08-22       Impact factor: 2.447

Review 3.  c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.

Authors:  Daniel Delitto; Eva Vertes-George; Steven J Hughes; Kevin E Behrns; Jose G Trevino
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

4.  The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients.

Authors:  Ji Hyung Hong; Kang San Roh; Sung-Suk Suh; Sukchan Lee; Sook Whan Sung; Jae Kil Park; Jae Ho Byun; Jin Hyoung Kang
Journal:  Tumour Biol       Date:  2015-06-25

Review 5.  Liposarcoma: molecular targets and therapeutic implications.

Authors:  Kate Lynn J Bill; Lucia Casadei; Bethany C Prudner; Hans Iwenofu; Anne M Strohecker; Raphael E Pollock
Journal:  Cell Mol Life Sci       Date:  2016-05-12       Impact factor: 9.261

6.  The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma.

Authors:  Kate Lynn J Bill; Jeannine Garnett; Xiaoyan Ma; Caitlin D May; Svetlana Bolshakov; Alexander J Lazar; Dina C Lev; Raphael E Pollock
Journal:  Lab Invest       Date:  2015-06-01       Impact factor: 5.662

Review 7.  Development of antibody-based c-Met inhibitors for targeted cancer therapy.

Authors:  Dongheon Lee; Eun-Sil Sung; Jin-Hyung Ahn; Sungwon An; Jiwon Huh; Weon-Kyoo You
Journal:  Immunotargets Ther       Date:  2015-02-09

8.  Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met.

Authors:  Yan Shu; Bo Xie; Zhen Liang; Jing Chen
Journal:  Oncol Lett       Date:  2017-12-08       Impact factor: 2.967

Review 9.  The role of MET in chemotherapy resistance.

Authors:  Georgina E Wood; Helen Hockings; Danielle M Hilton; Stéphanie Kermorgant
Journal:  Oncogene       Date:  2021-02-01       Impact factor: 9.867

10.  A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.

Authors:  Douglas C Marchion; Elona Bicaku; Yin Xiong; Nadim Bou Zgheib; Entidhar Al Sawah; Xiaomang Ba Stickles; Patricia L Judson; Alex S Lopez; Christopher L Cubitt; Jesus Gonzalez-Bosquet; Robert M Wenham; Sachin M Apte; Anders Berglund; Johnathan M Lancaster
Journal:  Oncol Rep       Date:  2013-03-05       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.